New Drug Shows Significant Improvement In HIV-related Heart Condition

by Medindia Content Team on  December 20, 2004 at 2:44 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

New Drug Shows Significant Improvement In HIV-related Heart Condition
Latest research has shown that treatment with the oral drug bosentan (Tracleer) has led to significant improvements in an often fatal disease, pulmonary arterial hypertension ( PAH) .

PAH is usually linked with human immunodeficiency virus infection. HIV infection is believed to cause the overproduction of endothelin, which increases the chance for small pulmonary arteries to become obstructed. This chronic obstruction leads to PAH, a condition that in most cases is the direct cause of death. Bosentan mediates the effects of excess endothelin production.

For the study 16 HIV-positive patients suffering from PAH who were treated with bosetan for 16 weeks were evaluated. Results showed there was significant improvement in survival indicators of the disease, such as six-minute walk distance and cardiac index, following bosetan treatment. However all patients suffered at least one adverse side effect of the drug including peripheral edema, headache, abnormal liver function, muscle cramps, fluid retention, and vomiting.

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Clinical Trials - Different Phases of the trial Signature Drug Toxicity Heart Healthy Heart Statins Mitral Valve Prolapse Aortic Valve Stenosis Pericarditis 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive